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Uroklnase-plasmlnogen activator is synthesized in vitro by human
glomerular epithellal cells but not by mesangial cells. The plasmin
protease system may have a role in maintaining the patency of renal
tubules and in regulating matrix degradation within the glomerulus.
Urokinase-plasminogen activator (u-PA) is a serine protease which
plays an important part in the regulation of plasmin production from
plasminogen. The synthesis of u-PA by cultured human glomerular
cells, in particular mesangial cells, is controversial. The present study
describes the presence of u-PA in supernatants of pure cultures of
human glomerular epithelial cells (EC), cocultures of EC and human
mesangial cells (MC) and whole glomeruli, but not within pure cultures
of MC. To confirm the synthesis of u-PA mRNA in glomerular EC,
cocultures of EC and MC were tested by in situ hybridization with u-PA
antisense and sense digoxigenin-labeled RNA probes. Cytoplasmic
localization of u-PA mRNA was demonstrated only in the EC, thus
confirming the absence of synthesis of u-PA by human mesangial cells
in culture.
Plasminogen activators are highly specific serine proteases
which convert the zymogen plasminogen into the active proteo-
lytic enzyme plasmin. The protease plasmin can degrade a
variety of matrix molecules as well as fibrin. The two types of
plasminogen activators, urokinase-plasminogen activator (u-
PA) and tissue-type plasminogen activator (t-PA), can be dis-
tinguished both physiologically and immunologically, and are
present in several tissues as well as in the supernatants from
different types of cultured cells. The production of plasmin by
plasminogen activators plays an important role in fibrinolysis
[1], cell migration [2] embryonic development and stromal
invasion by malignant cells [3].
U-PA is present in high concentration in urine but its func-
tional role in the kidney is still not fully understood. It has been
suggested that through the activation of plasmin, u-PA may
encourage the removal of intraluminal fibrin or extracellular
matrix components obstructing urinary flow [4]. Indeed, the
maintenance of tubular patency and fluidity may be the major
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function of u-PA in a variety of organs [3]. Recent work has
suggested that u-PA synthesis by rat glomerular cells may be
important in regulating glomerular matrix accumulation, with
reduced u-PA production in whole giomeruli from nephritic rats
implicated as a contributory factor in decreasing glomerular
matrix degradation and thus in promoting disease progression
[5]. The clinical significance of findings in animal models of
glomerulonephritis is obviously reliant upon their relevance to
human cells and tissues. In particular, the site of u-PA synthesis
in human kidney, notably within the glomerulus, is uncertain.
Studies in normal mouse tissues show u-PA immunoreactivity
and u-PA mRNA within medullary rays and portions of proxi-
mal and distal tubules [4, 6]. A similar distribution of u-PA
immunoreactivity has been noted within normal human kidney
[7, 8] with no glomerular staining being reported, although an in
vitro study has shown u-PA to be localized within cultured
epithelial cells (EC) derived from human glomeruli [9].
The production of u-PA by human mesangial cells (MC) is
also controversial. Lacave and co-workers [10] identified plas-
minogen activator inhibitor-i (PAT-i) and t-PA, but not u-PA, in
supernatants from cultured MC. Recent work, including that
from our own laboratory, has claimed, however, that MC do
produce u-PA in concentrations significantly greater than that
oft-PA [11, 12].
The aim of the present in vitro study was to investigate the
synthesis of u-PA by cultured human glomerular cells and
cultured whole human glomeruli through measurement of pro-
tein production and by detection of u-PA mRNA.
Methods
Cell and whole glomerular cultures
Human glomerular EC and MC and whole glomeruli were
cultured from the renal cortex of histologically normal portions
of the non-involved poles of tumor nephrectomy specimens.
Glomeruli were isolated by a standard three-stage sieving
method [13], by passing the renal cortex sequentially through
stainless steel sieves of sizes 250, 150 and 106 j.tm. The smallest
pore size retained the glomeruli, which were either transferred
directly to six-well plastic plates and used immediately for
whole glomerular culture (plated in triplicate at 500 glomeruli
per 7 ml of culture medium with assay of supernatant after 48
hr) or, for MC and EC culture, transferred into 80 cm3 tissue
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culture flasks. The glomeruli were cultured in RPMI 1640
medium supplemented with 2 mvx L-glutamine, 100 lU/mi
penicillin, 100 J.Lg/ml streptomycin with 10% fetal calf serum, 5
g/m1 insulin, 5 g/ml transferrin and 30 ms selenium growth
supplement. The cultures were incubated at 37°C in a humidi-
fied 5% CO2 incubator. Smooth muscle-like MC appeared from
the glomeruli around 8 to 14 days after attachment. They were
allowed to stack alter confluency until they outgrew all EC
present. Cells were used between passes 3 and 5. Cocultures of
MC and EC were prepared by passing cells just before they
reached confluence. EC were prepared from glomeruli by
selecting groups of homologous cells, identified by their mor-
phological features. They were grown in RPMI 1640 medium
supplemented as above, but containing only 2.5% fetal call
serum. Triiodo-thyroxin (25 ng/ml), prostaglandin Al (25 ng/ml)
and epidermal growth factor (10 ng/ml) were also included in the
growth medium. Epidermal growth factor was omitted from the
growth medium at pass 2. All experiments on EC were per-
formed at pass 3. Cells were cultured in 24 well plates contain-
ing 1 ml of medium per well. Experiments were performed in
triplicate either at approximately 50% confluence or after cells
had just reached confluence. All cell preparations employed
were immunocytochemically characterized.
Immunocytochemistry
Cultured cells on plastic eight-chambered Permanox plastic
slides (Nunc) were washed in phosphate buffered saline (PBS)
then fixed for 10 minutes in cold acetone. Antibody binding was
visualized using the standard APAAP technique [14]. Slides
were counterstained with Harris's hematoxylin. Two percent
BSA in Tris buffered saline was used as a negative control.
Testing was undertaken with monoclonal antibodies against
cytokeratin (LP34/Dakopatts, Copenhagen, Denmark), von
Willebrand's factor (F8/86fDakopatts), smooth muscle specific
actin (NH3/Serotec) and F2 18, a monoclonal antibody previ-
ously shown to have specific staining for MC and proximal,
distal and collecting duct epithelium, but not glomerular EC or
endothelial cells [13]. The relative proportion of EC and MC in
cocultures was evaluated by counting 200 cells in the cytoker-
atm-stained preparations. Pure MC cultures were designated as
such only if cytokeratin positive cells were unidentifiable in
such preparations.
Preparation of probes
A 1500 kbp Pst-1 and Barn Hi fragment of human u-PA
cDNA (pHUK-8 American Type Culture Collection) was sub-
cloned into the transcription plasmid pSPT18 (Boehringer
Mannheirn, East Sussex, UK) using standard techniques [15].
Purified plasmid was prepared and linearized either with Pst-1
or Barn Hi. One microgram of linearized plasmid was used as a
template, and labeled riboprobe (sense or antisense) was pre-
pared using the SP6/T7 transcription kit (Boehringer) with the
inclusion of digoxigenin-labeled UTP. Unincorporated nude-
otides were removed on a Sephadex G50 Nick column (Phar-
macia, Uppsaia, Sweden). Control DNA/RNA dot/blot hybrid-
ization was performed using nylon membranes following the
method described by the supplier (Boehringer).
Hybridization procedure
The hybridization method employed was based on proce-
dures described by Boehringer. All procedures, with the excep-
tion of the hybridization step, were undertaken by immersing
the slides into solutions. Adherent cells on multiwell plastic
slides were fixed in freshly prepared 0.4% paraformaldehyde
(BDH Chemicals) for 20 minutes. Briefly, the slides were
subjected to the following pretreatments: 0.3% Triton X-100 for
15 minutes; 0.2 M HCI for 15 minutes; digestion with 20 #zg/ml
proteinase K (Sigma) for one minute at 37°C; post-fixation with
0.4% paraformaldehyde; and 0.5% acetic anhydride (Sigma) in
0.1 M triethanolamine (Sigma) for 10 minutes. The slides were
washed in 2x saline sodium phosphate EDTA (SSPE, Sigma)
between pretreatments.
The hybridization mixture contained the digoxigenin-labeled
RNA probe (2.5 ng/jsl), 50% deionized formamide (Fluka), 4x
saline sodium citrate (SSC), lx Denhardt's solution (Sigma),
0.5 mg/ml heat-denatured salmon testis DNA (Sigma), 0.25
mg/mi tRNA (Sigma) and 0.1% dextran sulphate (Sigma). The
slides were incubated with the probe at 50°C overnight; half the
slide was used for hybridization with the antisense probe and
half for the sense probe. The post-hybridization washes con-
sisted of 2x SSC at 50°C for 10 minutes, 2x SSC in 50%
formamide at 65°C for 45 minutes and 4x SSPE at 50°C for 5
minutes. Digestion of non-hybridized RNA was achieved using
20 pg/mi RNAse A (Boehringer) at 37°C for 30 minutes. This
was followed by washes in 2 x SSC in 50% formamide at 65°C
for 45 minutes and 2x SSC at 50°C for 5 minutes. Immunolog-
ical detection involved: washes in 0.1% Tween 20 in PBS
(PBST); 1% blocking buffer in PBST; a 1:5000 dilution of
anti-digoxigenin-alkaline phosphatase conjugated antibody(Boehringer); 3 washes in PBST; and color detection in a
solution comprising 100 ml of 0.1 M NaC1, 0.05 M MgC12, 0.1 M
Tris, pH 9.5, 0.1% Tween 20, 45 .d of nitroblue tetrazolium, 35
p1 of X phosphate solution (Boehringer) and seven drops
levamisole solution (Vector Laboratories). The color reaction
was stopped with 10 m Tris, pH 7.8, 10 mri EDTA for S
minutes. Slides were either counterstained with neutral fast red
or immediately processed for further immunocytochemistry
using the standard APAAP technique already described.
Measurement of u-PA in supernatants
ELISA. The u-PA concentration was determined using the
Biopool TintElize u-PA kit according to the manufacturer's
instructions. The kit measures all forms of u-PA; single chain
and high molecular weight u-PA are detected with approxi-
mately the same efficiency while low molecular weight u-PA is
measured to about 25% efficiency of the other forms. The kit is
sensitive to 100 pg/ml. Results were expressed as ng u-PA!
well/48 hours.
Zymography. Low concentrations of u-PA (free and com-
plexed with PAl-i) were detected by zymography as previously
described [16]. Briefly, supernatant from cells (10 1.d) was
subjected to electrophoresis in 10% polyacrylamide gel slabs
containing 0.1% SDS. The gels were then washed in 2.5%
Triton X-100 to remove the SDS. After rinsing in distilled
water, the gels were layered on indicator gel slabs containing
1% agar, plasminogen (50 g/ml), thrombin (0.03 U/mi) and
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Table 1. U-PA in supernatants from glomerular cell and whole kDa
glomerular cultures
Group
Culture
no. % EC
u-PA
ng/wel1
EC 1
2
100
100
1044±140
1364±130
Mixed culture 1
2
3
99
20
15
1220 200
150±80
293±80
MC 1
2
0
0
ND
ND
Whole glomerulid
EC (non-confluent)
1
2
1
2
—
—
100
100
10.6 3.4
3.0±0.4
740 44
181±27
a Standard deviations were calculated from cultures performed in
triplicate; u-PA concentration was measured by Biopool TintElize u-PA
kit following manufacturer's instructionsb Cultures were expressed as ng u-PA/well/48 hours (on average
confluent wells contained 9 x iO cells/well whereas non-confluent
wells contained 4.7 x io cells/well)
C ND represents not detectable
LI Whole glomeruli were plated immediately after separation by
sieving. Plating was at 500 glomeruli per 7 ml supplemented RPM!
medium
flbrinogen (2 mg/ml). Plasminogen activator activity was visu-
alized as clear bands of lysis in the opaque fibrin-agar indicator
gel. U-PA or t-PA antibodies were included in the detector
plates as appropriate [16].
Results
Characterization of cells
A total of nine glomerular cell cultures were immunocyto-
chemically screened. Two cultures were identified as pure MC
with generalized positivity for F218 and smooth muscle-cell
specific actin and negativity for cytokeratin. Four cultures were
pure EC with generalized positivity for cytokeratin and nega-
tivity for F2 18. Three cultures were mixed cultures which
comprised 15%, 20% and 99% EC, the remainder in each case
being mesangial cells. No cells stained positively for von
Willebrand's factor—an endothelial cell marker.
Assay of u-PA
ELISA. Supernatants from pure EC and mixed cultures (from
confluent cultures unless stated otherwise) contained significant
amounts of u-PA as detected by ELISA (Table 1). A single
mixed cell culture comprising 99% EC produced amounts of
u-PA similar to those measured in pure EC cultures. Superna-
tants from whole glomerular cultures contained small amounts
of u-PA. Neither of the two pure MC cultures produced
detectable amounts of u-PA. Two pure cultures of non-conflu-
ent EC produced appreciable amounts of u-PA.
Zymography. Plasminogen activator activity was visualized
by flbrin agar indicator gels after SDS-PAGE. The broad band
at 55 to 60 KDa representing fibrin lysis was due to u-PA as
shown by inhibition with a specific antibody (data not shown).
The presence of u-PA activity, as detected by zymography, was
confirmed in the supernatants from pure EC, mixed cultures,
whole glomerular cultures and non-confluent pure EC: no u-PA
a b c d e
Fig 1. Zymography for plasminogen activators with the band at 50 to
60 kDa showing u-PA activity. Lanes a, b, c, d and e represent
supernatants from EC, mixed culture, MC, whole glomeruli and non-
confluent EC, respectively. U-PA activity was not identified in the MC
culture.
was detected in MC (Fig. 1). A complex of t-PA and PA!-! was
observed at 110 KDa for MC; no free t-PA was present.
Detection of u-PA mRNA
In situ hybridization for u-PA mRNA with the antisense
probe revealed perinuclear localization within only one popu-
lation of cells within the cocultures. The distribution of positive
cells corresponded to the distribution of EC as detected by
immunocytochemistry. Subsequent double staining for cyto-
keratin after in situ hybridization revealed u-PA mRNA local-
ization only within those cells expressing this epithelial marker
(Fig. 2a). Cytokeratin staining was diffusely cytoplasmic. Dou-
ble labeling with the control sense RNA probe and cytokeratin
revealed a similarly distributed expression of the epithelial
marker in the absence of u-PA mRNA localization (Fig. 2b).
Discussion
These studies demonstrate that cultured human glomerular
EC synthesize u-PA, while MC do not. Production of u-PA by
—110
—50—60
46 Brown et al: Urokinase in cultured glomerular cells
Fig. 2. Localization of u-PA mRNA and cytokeratin filaments within cocultures of glomerular EC and MC. In situ hybridization with the antisense
RNA probe reveals the presence of perinuclear granular blue staining for u-PA mRNA, only in those cells which show diffuse pink cytoplasmic
staining for cytokeratin (A). MC nuclei (arrow) are negative for both u-PA mRNA and cytokeratin immunostaining. Control experiments
incorporating in situ hybridization with sense RNA probe reveal absence of positivity for u-PA mRNA in cells staining positively for cytokeratin
(B) (A and B hematoxylin counterstain x 466). Reproduction of this figure in color is made possible by a grant from the Welcome Trust, United
Kingdom.
MC has, however, been reported [11, 12] with markedly higher
levels of u-PA as compared to t-PA being detected [12]. These
apparently conflicting results could have two possible explana-
tions. Firstly the MC might be expressing different phenotypes
as cultured cells. The MC may be behaving phenotypically
more like monocyte-macrophages, which produce both u-PA
and PAI-2, but not PAl-i [17], than smooth muscle cells which
produce only PAl-i [18]. Our results agree with those of Lacave
and coworkers [10], whose group found no u-PA production by
pure MC but did find production of PAl-i and t-PA. Lacave
postulated that MC in culture behave phenotypically more like
vascular smooth muscle cells. The second possible explanation
is that the apparent production of u-PA by MC might have
arisen through contamination by EC, a problem we now believe
to be true of our previous cultures [11]. Our recent results
suggest that cocuitures of MC and BC can result in easily
detectable levels of u-PA, even when MC predominate. Con-
tamination of MC by EC must, therefore, be excluded in
glomerular cell culture work before assay of MC supernatants
for u-PA.
Detection of u-PA antigen within supernatants was achieved
using an ELISA method and by the more sensitive technique of
zymography which allows low concentrations of plasminogen
activators, both free and complexed with PAT-i, to be detected.
U-PA mRNA within glomerular EC was demonstrated by a
combination of non-isotopic in situ hybridization and immuno-
cytochemistry—a method that can provide unequivical proof of
synthesis by a particular cell type. Burgess et al [19] have
pointed to the suitability of double alkaline phosphatase stain-
ing for detecting two different antigens on the same cytospin
preparation, whether the antigens are exclusively distributed on
different cells or are localized within different compartments of
the same cell. Our results show the suitability of using a double
alkaline phosphatase method for detecting perinuclear mRNA
and cytoplasmic antigen within the same cell.
The production in culture of u-PA by glomerular epithelial
cells is interesting in view of the absence of immunocytochem-
ically identifiable u-PA within sections of normal and diseased
human glomeruli [20, 21]. Minor staining for u-PA has been
identified in only one case of human crescentic glomerulone-
phritis with positivity being confined to crescents [20]. Further-
more, u-PA mRNA has been localized within sections of normal
mouse kidney to proximal, distal and collecting tubules in the
outer part of the medulla, but not within glomerular cells.
Research on a rat model of experimental glomerulonephritis
has, however, implicated an imbalance in the relative amounts
of u-PA and PAl- 1 in promoting matrix accumulation within
cultured whole glomeruli from nephritic animals [5]. These
experimental results probably reflect a variety of interspecies
and in vivo/in vitro differences in u-PA production, and it is
interesting to speculate as to why u-PA is not identified within
glomeruli in human tissue sections. U-PA synthesis by cultured
EC may simply reflect dedifferentiation as glomerular EC are
constantly proliferating in culture, a situation which is unlikely
in the normal kidney. Marked dedifferentiation of cells would,
however, be much less likely to occur in whole giomerular
cultures. The low levels of u-PA production by our whole
glomerular cultures, although not directly comparable, might
indicate an intermediate state between the glomerulus in vivo
and cultured EC, the latter producing large amounts of u-PA.
An alternative explanation for the apparent absence of u-PA
within glomeruli in tissue sections might be that u-PA is not
identifiable within the cytoplasmic compartment in vivo, as the
protein is exported in a non-immunogenic form. Recent work
has shown that PAl- 1, an inhibitor of u-PA, is identified
immunocytochemically in the pericellular environment of cul-
tured MC, although PAT-i mRNA can be localized within the
cytoplasm [22]. These results reinforce the importance of in situ
hybridization in providing evidence for synthesis. Furthermore,
the same authors have shown that cell to cell contact can have
an important bearing on whether cells synthesize a particular
protein. They demonstrate that cultured MC deposit PAl-i in
the extracellular matrix, not cytoplasmically, when they are
nonconfluent and spreading, but not when they are confluent.
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From their data they have postulated that PAl-i is not detected
within MC in normal human renal biopsies as the glomerulus
may represent a confluent environment. The lack of evidence
for u-PA immunolocalization within the glomerulus might sim-
ilarly reflect the slow turnover of confluent visceral EC which,
even in disease, show remarkably little proliferative activity. In
our experiments, however, u-PA was produced by both conflu-
ent and proliferating, non-confluent EC, suggesting that conflu-
ence has little effect on these cells in vitro. The production of
u-PA in vitro by EC may therefore simply reflect dedifferenti-
ation. This emphasizes the importance of identification, or with
much more difilculty, the confirmation of the absence, of u-PA
mRNA within the normal and diseased human glomerulus in
vivo.
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